StockData

Ocular Therapeutix vs Xilio Therapeutics

OCUL and XLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OCUL and XLO compare

Ocular Therapeutix is the larger company, worth 30 times as much as Xilio Therapeutics ($1.3B against $44.5M).

Xilio Therapeutics grew revenue faster over the last twelve months (327% versus −8.1% for Ocular Therapeutix).

Xilio Therapeutics keeps more of each dollar of sales as profit, with a net margin of −34.1% compared with −579% at Ocular Therapeutix.

Xilio Therapeutics scores higher on the StockData Score (11 against 3 for Ocular Therapeutix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOCULXLO
Size and price
Market cap$1.3B$44.5M
Share price$6.01$7.70
Change, 1 year−46.3%−21.6%
Change, 5 years−8.1%−97.2%
Beta (5Y)1.53−0.00
Employees32576
StockData Score
Total score311 (better)
Valuation score03 (better)
Growth score01 (better)
Performance score02 (better)
Health score35 (better)
Dividend score00
Valuation
P/S25.4×0.7× (better)
P/B2.5×0.6× (better)
FCF yield−19.3% (better)−138%
Fair value$5.43$39.24
Margin of safety−10.7%80.4% (better)
Growth
Revenue growth (TTM)−8.1%327% (better)
Revenue growth, 5Y average24.4%–
Profitability
Gross margin87.1%–
Operating margin−603%−48.9% (better)
Net margin−579%−34.1% (better)
FCF margin−490%−95.6% (better)
Return on equity−73.0%−55.0% (better)
Financial health
Debt / equity0.14 (better)0.00
Interest coverage−27.5×–
Current ratio13.11 (better)4.25
Altman Z-score2.07 (better)−3.01
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions94.4%58.9%
Held by insiders2.9%–
Insider net buying, 12 months−$2.5M$38.3K (better)
Short interest, % of float13.6%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.